UCB's planned acquisition of Candid for up to $2.2 billion aims to enhance its portfolio in TCE antibodies for autoimmune diseases. This deal follows a previous licensing agreement with Antengene, signaling a strategic shift towards platform-based treatments.
Why it matters. UCB is increasing its competitive edge against companies like AbbVie and Amgen in the immunology space.
Our readExpect UCB to leverage this acquisition to diversify its immunology pipeline — watch for updates on clinical trials.
Source · GEN News
CellCentric has secured $220 million in Series D funding to expedite the development of its oral therapy for multiple myeloma. This financing comes as the company aims to address treatment gaps for patients with limited options.
Why it matters. This financing comes as the company aims to address treatment gaps for patients with limited options.
Our readCellCentric's strong funding round suggests significant investor confidence in its therapeutic potential — expect a clinical trial announcement soon.
Source · Endpoints News
Novelty Nobility is expanding its collaboration with AGC Biologics to advance a product candidate through GMP manufacturing. The project involves tech transfer from Copenhagen to Chiba, Japan, indicating a robust global manufacturing strategy.
Why it matters. The project involves tech transfer from Copenhagen to Chiba, Japan, indicating a robust global manufacturing strategy.
Our readNovelty Nobility's strategic move highlights the increasing importance of global manufacturing networks in biotech; anticipate further developments in this space.
Source · GEN News
Blade Air Mobility reported a Q1 GAAP EPS of $0.03, beating estimates by $0.07, with revenues of $67.4 million exceeding expectations by $3.73 million. The results highlight the growing demand for urban air mobility solutions.
Why it matters. The results highlight the growing demand for urban air mobility solutions.
Our readBlade's earnings suggest a strong growth trajectory; keep an eye on its expansion plans in urban markets.
Source · Seeking Alpha Biotech
New findings from Viridian's Phase 3 trial for its thyroid eye disease drug show improved efficacy in chronic patients, contrasting earlier disappointing results. Analysts view this data as competitive against Amgen's Tepezza.
Why it matters. Analysts view this data as competitive against Amgen's Tepezza.
Our readViridian's data turnaround is significant; expect increased investor interest and potential for partnership discussions.
Source · BioPharma Dive